Extended-spectrum β-lactamases, carbapenemases and the mcr-1 gene: is there a historical link?

被引:33
|
作者
Rhouma, Mohamed [1 ,2 ,3 ]
Letellier, Ann [1 ,2 ,3 ]
机构
[1] Univ Montreal, Fac Med Vet, Chaire Rech Ind CRSNG Salubrite Viandes CRSV, 3200 Rue Sicotte, St Hyacinthe, PQ J2S 7C6, Canada
[2] Univ Montreal, Fac Med Vet, GRESA, 3200 Rue Sicotte, St Hyacinthe, PQ J2S 7C6, Canada
[3] Univ Montreal, Fac Med Vet, CRIPA, 3200 Rue Sicotte, St Hyacinthe, PQ J2S 7C6, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
Extended-spectrum beta-lactamase; Carbapenemase; mcr-1; Gene; Colistin; PLASMID-MEDIATED COLISTIN; ESCHERICHIA-COLI; RESISTANCE GENE; EMERGENCE;
D O I
10.1016/j.ijantimicag.2016.11.026
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The plasmid mediated mcr-1 gene encoding for Enterobacteriaceae colistin resistance has been recently identified across five continents. The objective of the present study was to trace historical events concerning the discovery and emergence of the mcr-1 gene along with ESBL and carbapenemase genes since several studies have reported identifying mcr-1 genes among Extended-Spectrum beta-Lactamases (ESBL) and/or carbapenemase producing Escherichia coli. A retrospective study reported the identification of the mcr-1 gene in E. coli strains isolated in the 1980s, and this seems to correspond to the first identification of ESBL enzymes. The first discovery of the New Delhi metallo-beta-lactamase-1 (NDM-1) in 2009 was associated with a significant increase in mcr-1 gene prevalence in E. coli strains obtained from food producing animals. We noticed that a historical link has existed between mcr-1, ESBL and carbapenemase genes since the 1980s, and we believe that the re-evaluation of colistin use in livestock needs an overall approach that includes not only colistin use reduction but also the reduction of all antibiotic use. (C) 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:269 / 271
页数:3
相关论文
共 50 条
  • [21] Genetic support of extended-spectrum β-lactamases
    Poirel, L.
    Naas, T.
    Nordmann, P.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2008, 14 : 75 - 81
  • [22] Extended-spectrum β-lactamases and the permeability barrier
    Martinez-Martinez, L.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2008, 14 : 82 - 89
  • [23] EXTENDED-SPECTRUM BETA-LACTAMASES
    PHILIPPON, A
    LABIA, R
    JACOBY, G
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (08) : 1131 - 1136
  • [24] Extended-spectrum beta-lactamases
    Patterson, JE
    [J]. SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 24 (01) : 79 - 87
  • [25] Extended-spectrum β-lactamases in Pseudomonas aeruginosa
    Nordmann, P
    Guibert, M
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (02) : 128 - 131
  • [26] Evolution of extended-spectrum β-lactamases by mutation
    Gniadkowski, M.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2008, 14 : 11 - 32
  • [27] Extended-spectrum β-lactamases -: A plague of plasmids
    Fierer, J
    Guiney, D
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (06): : 563 - 564
  • [28] Epidemiology of extended-spectrum β-lactamases -: Response
    Jacoby, GA
    [J]. CLINICAL INFECTIOUS DISEASES, 1998, 27 (01) : 81 - 83
  • [29] Addressing the challenge of extended-spectrum β-lactamases
    Zahar, Jean-Ralph
    Lortholary, Olivier
    Martin, Claude
    Potel, Gilles
    Plesiat, Patrick
    Nordmann, Patrice
    [J]. CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2009, 10 (02) : 172 - 180
  • [30] Metallo-β-lactamase, extended spectrum β-lactamase and mcr-1 gene as major therapeutic challenges
    Talebi, Ghazaleh
    Hashemi, Ali
    [J]. REVIEWS AND RESEARCH IN MEDICAL MICROBIOLOGY, 2022, 33 (01): : E40 - E47